Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Multicenter, Open Label, Two-part Study (Single Ascending Dose [Part 1], and Dose Expansion [Part 2]) to Evaluate Safety, Tolerability and Efficacy of PS-002, a Gene Therapy for the Treatment of Adult Participants With Primary IgA Nephropathy
Conditions
Interventions
PS-002
Locations
11
United States
University of Miami Hospital
Miami, Florida, United States
The Johns Hopkins Hospital
Baltimore, Maryland, United States
University of Michigan Hospital
Ann Arbor, Michigan, United States
Manchester University NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom
Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom
Leicester General Hospital
Leicester, Leicestershire, United Kingdom
Start Date
February 1, 2026
Primary Completion Date
September 1, 2028
Completion Date
September 1, 2029
Last Updated
March 20, 2026
Lead Sponsor
Purespring Therapeutics Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions